Medical Advocates
HIV Drug Monitoring
  ARV Drug Resistance Monitoring
Drug-Specific Studies

Abacavir
Atazanavir
Efavirenz
 Lopinavir
Nelfinavir
Nevirapine
Saquinavir
Tipranavir
Tenofovir

 
HIV Therap. Monitoring Main Main New//Newsworthy Home Page      
Last Update:  May 24, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Abacavir
       
     Journal Papers, Abstracts, and Commentaries
 
  Clinically relevant interpretation of genotype for resistance to abacavir.
Brun-Vezinet F, Descamps D, Ruffault A, et al  
AIDS. 2003 Aug 15;17(12):1795-1802
 Abstract
Atazanavir
       
     Journal Papers, Abstracts, and Commentaries
 
 
Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir
Trough Concentrations in HIV-Infected Patients During Therapeutic Drug Monitoring.
Slish J, Ma Q, Zingman BS, et al 
Ther Drug Monit. 2007 Oct;29(5):560-565.
Abstract

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
 Cleijsen RM, van de Ende ME, Kroon FP, et al
J Antimicrob Chemother. 2007 Aug 17;
 Abstract
Efavirenz
       

      Journal Papers, Abstracts, and Commentaries

 
Efavirenz and Nevirapine in HIV-1 Infection : Is There a Role for Clinical Pharmacokinetic
Monitoring?
Dahri K, Ensom MH.
Clin Pharmacokinet. 2007;46(2):109-32.
 Abstract

Efavirenz Plasma Concentrations in HIV-Infected Patients: Inter- and Intraindividual Variability
and Clinical Effects.
Stahle L, Moberg L, Svensson JO, Sonnerborg A.
Ther Drug Monit. 2004 Jun;26(3):267-270.
 Abstract

     Conference Reports, Abstracts, and Posters

 
PDF POSTER
 Therapeutic Drug Monitoring of Efavirenz in HIV-infected patients treated by Sustiva associated
or not with ritonavir.
 S Faroux,  M Berhoune ,  H Sauvageon-Martre, et al
4th Int Workshop on Clin Pharmacology of HIV
 Poster

Efavirenz and Nevirapine concentration-effect relationships in HIV infected patients
pharmacologically followed by routine therapeutic drug monitoring (TDM)
Garraffo R, Lavrut T, Pierre B, et al.
4th Int Workshop on Clin Pharmacology of HIV
 Abstract
Lopinavir
       

     Journal Papers, Abstracts, and Commentaries

 
Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir
Trough Concentrations in HIV-Infected Patients During Therapeutic Drug Monitoring.
Slish J, Ma Q, Zingman BS, et al 
Ther Drug Monit. 2007 Oct;29(5):560-565.
Abstract
 
Drug monitoring and viral response to Lopinavir/Ritonavir or Saquinavir/Ritonavir
containing regimens in individuals infected with the human immunodeficiency virus type 1.
Falkensammer B, Fasser W, Scherer K, et al  Int
J Immunopathol Pharmacol. 2005 January-March;18(1):145-154
 Abstract
 
Simplification of Therapeutic Drug Monitoring for Twice-Daily Regimens of
Lopinavir/Ritonavir for HIV infection.
Alexander CS, Montaner JS, Asselin JJ, et al 
Ther Drug Monit. 2004 Oct;26(5):516-523.
 Abstract

Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside
reverse transcriptase inhibitor.
Solas C, Poizot-Martin I, Drogoul MP, et al  
Br J Clin Pharmacol. 2004 Apr;57(4):436-40.
 Abstract

     Conference Reports, Abstracts, and Posters
 
 
A Computer Artificial Intelligence System to Aid in the Interpretation of Plasma
Lopinavir and Efavirenz Drug Concentrations
M Goicoechea, A Vidal, E Capparelli, et al
(12 CROI)
Abstract

POSTER
 Simplifying Therapeutic Drug Monitoring for Twice Daily Regimens of Kaletra
C Alexander J. Montaner,  J. Asselin et al
(4th Int Workshop on  Clin Pharmacology of HIV)
 PDF Poster
Nelfinavir
       
    
     Journal Papers, Abstracts, and Commentaries
 
 
Limited Sampling Strategy for the Estimation of Systemic Exposure to the Protease
Inhibitor Nelfinavir.
Regazzi MB, Tinelli C, Villani P, et al
 Ther Drug Monit. 2005 Oct;27(5):571-575.
 Abstract

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naiveHIV-1-infected
individuals.
Burger D, Hugen P, Reiss P, et al.
AIDS. 2003 May 23;17(8):1157-1165.
Abstract
Nevirapine
       

     Journal Papers, Abstracts, and Commentaries

  Efavirenz and Nevirapine in HIV-1 Infection : Is There a Role for Clinical Pharmacokinetic
Monitoring?
Dahri K, Ensom MH.
Clin Pharmacokinet. 2007;46(2):109-32.
 Abstract

     Conference Reports, Abstracts, and Posters

  Efavirenz and Nevirapine concentration-effect relationships in HIV infected patients
pharmacologically followed by routine therapeutic drug monitoring (TDM)
Garraffo R, Lavrut T, Pierre B, et al.
(4(th Int Workshop on Clin Pharmacology of HIV)
 Abstract
Saquinavir
       

SQV/RTV
    
     Journal Papers, Abstracts, and Commentaries
 
  Drug monitoring and viral response to Lopinavir/Ritonavir or Saquinavir/Ritonavir
containing regimens in individuals infected with the human immunodeficiency virus type 1.
Falkensammer B, Fasser W, Scherer K, et al  Int
J Immunopathol Pharmacol. 2005 January-March;18(1):145-154
 Abstract
 
Tipranavir
       

     Conference Reports, Abstracts, and Posters
 
  Therapeutic Drug Monitoring of Boosted Tipranavir with and without Combination to Lopinavir or
Fosamprenavir
G Peytavin, A Marcelin, A Rouault,  et al
(!3 CROI)
 Abstract
Tenofovir
       

     Journal Papers, Abstracts, and Commentaries

 
  Relevance of a combined UV and single mass spectrometry detection for the determination of
tenofovir in human plasma by HPLC in therapeutic drug monitoring.
Barkil ME, Gagnieu MC, Guitton J.
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 19;

HIV Therap. Monitoring Main Main New//Newsworthy Home Page      

ARV Drug Resistance Monitoring Drug-Specific Studies